Inclusion Criteria:

          -  Signed, written informed consent by subject or legal representative prior to any
             trial-specific screening procedure

          -  Male or female, greater than or equal to (>=) 18 years of age (or having reached the
             age of majority according to local laws and regulations

          -  Measurable disease confirmed by an independent review committee (IRC) in accordance
             with RECIST version 1.1

          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1

          -  A female subject is eligible to participate if she is not pregnant, not breastfeeding,
             and at least one of the following conditions applies:

          -  Not a woman of childbearing potential OR

          -  A woman of childbearing potential who agrees to use a highly effective contraception

          -  A male subject must agree to use and to have their female partners of childbearing
             potential to use a highly effective contraception

          -  Histologically or cytologically confirmed advanced (locally advanced or metastatic)
             NSCLC (all types including squamous and sarcomatoid)

          -  Treatment naïve patients in first-line or pretreated patients with no more than 2
             lines of prior therapy

          -  Subjects with MET alterations, namely METex14 skipping alterations in plasma and/or
             tissue as determined by the central laboratory or by an assay with appropriate
             regulatory status

        Exclusion Criteria:

          -  Subjects with characterized Epidermal Growth Factor Receptor (EGFR) activating
             mutations that predict sensitivity to anti-EGFR-therapy

          -  Subjects with characterized Anaplastic Lymphoma Kinase (ALK) rearrangements that
             predict sensitivity to anti-ALK therapy

          -  Subjects with symptomatic brain metastases who are neurologically unstable

          -  Any unresolved toxicity Grade 2 or more according to National Cancer Institute Common
             Terminology Criteria for Adverse Events (NCI-CTCAE) from previous anticancer therapy

          -  Need for transfusion within 14 days prior to the first dose of trial treatment

          -  Prior chemotherapy, biological therapy, radiation therapy, hormonal therapy for
             anti-cancer purposes, targeted therapy, or other investigational anticancer therapy
             (not including palliative radiotherapy at focal sites) within 21 days prior to the
             first dose of trial treatment;

          -  Subjects who have brain metastasis as the only measurable lesion

          -  Inadequate hematological, liver, renal, cardiac function

          -  Prior treatment with other agents targeting the Hepatocyte Growth Factor c(HGF/c) -Met
             pathway

          -  Hypertension uncontrolled by standard therapies (not stabilized to < 150/90 mmHg)

          -  Past or current history of neoplasm other than Non-small Cell Lung Cancer (NSCLC),
             except for curatively treated non-melanoma skin cancer, in situ carcinoma of the
             cervix, or other cancer curatively treated and with no evidence of disease for at
             least 5 years

          -  Medical history of difficulty swallowing, malabsorption, or other chronic
             gastrointestinal disease, or conditions that may hamper compliance and/or absorption
             of the test product

          -  Major surgery within 28 days prior to Day 1 of trial treatment

          -  Known infection with human immunodeficiency virus, or an active infection with
             hepatitis B or hepatitis C virus

          -  Substance abuse, active infection, or other acute or chronic medical or psychiatric
             condition or laboratory abnormalities that might increase the risk associated with
             trial participation at the discretion of Investigators

          -  Known hypersensitivity to any of the trial treatment ingredients

          -  Legal incapacity or limited legal capacity

          -  Any other reason that, in the opinion of the Principal Investigator, precludes the
             subject from participating in the trial

          -  Participation in another clinical trial within the past 30 days